<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463837</url>
  </required_header>
  <id_info>
    <org_study_id>JUUL-JUUL-CTP-001(755-00041)</org_study_id>
    <nct_id>NCT03463837</nct_id>
  </id_info>
  <brief_title>Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers</brief_title>
  <acronym>Diamond</acronym>
  <official_title>A Randomized, Open-Label, Parallel-Group Study to Characterize Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% Electronic Nicotine Delivery Systems (ENDS) in Adult Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juul Labs, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Juul Labs, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The JUUL 5% Electronic Nicotine Delivery System (ENDS) is being studied as an alternative to
      combustible cigarette use. This study aims to find out how much nicotine is in the blood and
      urine of healthy adult subjects after using three JUUL 5% ENDS compared to smoking usual
      brands of combustible cigarettes and stopping smoking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will serve as a clinical evaluation of the exclusive use of selected JUUL ENDS,
      with the purpose of gaining an understanding of toxicant exposure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in primary biomarkers day 5 values for each JUUL 5% product will be compared to baseline:</measure>
    <time_frame>[Time Frame: 5 days]</time_frame>
    <description>Change in ; Urine N nitrosonornicotine (NNN), 4 (methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), 3 hydroxypropylmercapturic acid (3-HPMA), monohydroxybutenylmercapturic acid (MHBMA), and S-phenyl mercapturic acid (S-PMA) &quot;Blood carboxyhemoglobin (COHb)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of 3-hydroxy-1-methylpropylmercapturic acid (HMPMA) in urine</measure>
    <time_frame>[Time Frame: 5 days]</time_frame>
    <description>Change in Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of 2-cyanoethyl-mercapturic acid (CEMA) in urine</measure>
    <time_frame>[Time Frame: 5 days]</time_frame>
    <description>Change in Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of 1-hydroxypyrene (1-OHP) in urine</measure>
    <time_frame>[Time Frame: 5 days]</time_frame>
    <description>Change in Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of Nicotine in urine</measure>
    <time_frame>[Time Frame: 5 days]</time_frame>
    <description>Change in Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of Cotinine in urine</measure>
    <time_frame>[Time Frame: 5 days]</time_frame>
    <description>Change in Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of trans-3'-hydroxycotinine in urine</measure>
    <time_frame>[Time Frame: 5 days]</time_frame>
    <description>Change in Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of Glucuronides in urine</measure>
    <time_frame>[Time Frame: 5 days]</time_frame>
    <description>Change in Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of Nicotine in blood</measure>
    <time_frame>[Time Frame: 5 days]</time_frame>
    <description>Change in Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of Cotinine in blood</measure>
    <time_frame>[Time Frame: 5 days]</time_frame>
    <description>Change in Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of trans-3'-hydroxycotinine in blood</measure>
    <time_frame>[Time Frame: 5 days</time_frame>
    <description>Change in Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum concentration (Cmax) Plasma pharmacokinetic (PK) of Nicotine</measure>
    <time_frame>[Time Frame: Day 7,</time_frame>
    <description>Nicotine absorption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in time to maximum concentration (Tmax) Plasma PK of Nicotine</measure>
    <time_frame>[Time Frame: Day 7,</time_frame>
    <description>Nicotine absorption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of area under the curve (AUC) Plasma PK of Nicotine</measure>
    <time_frame>[Time Frame: Day 7,</time_frame>
    <description>Nicotine absorption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product use over 5-day period and during 5-minute fixed and ad libitum use episodes</measure>
    <time_frame>[Time Frame: 7 days]</time_frame>
    <description>Change in product use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of subjective Smoking Urge Assessment</measure>
    <time_frame>[Time Frame: 6-7 days, intervention dependent]</time_frame>
    <description>Change in Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of subjective product evaluation using the &quot;modified Product Evaluation Scale (mPES)&quot;</measure>
    <time_frame>[Time Frame: 6-7 days, intervention dependent]</time_frame>
    <description>Change in Evaluation; Scale: 1 = not at all, 2 = very little, 3 = a little, 4 = moderately, 5 = a lot, 6 = quite a lot, 7 = extremely
Four multi-item subscales will be derived from &quot;Satisfaction&quot; (items 1, 2, 3, and 12); &quot;Psychological Reward&quot; (items 4 through 8); &quot;Aversion&quot; (items 9, 10, 16, and 18); and &quot;Relief&quot; (item 11, 13, 14, 15, and reversed for item 19) and single items 17 and 20 will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of future intent to use JUUL 5% Device device relative to usual combustible cigarette and smoking cessation.</measure>
    <time_frame>[Time Frame: 6-7 days, intervention dependent]</time_frame>
    <description>Change in Intent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events associated with use of JUUL 5% Device to combustible cigarette and smoking cessation</measure>
    <time_frame>[Time Frame: 13-14 days, intervention dependent]</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of JUUL 5% Device, including malfunction and/or misuse</measure>
    <time_frame>[Time Frame: 7 days]</time_frame>
    <description>Device performance</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Nicotine Dependence, Other Tobacco Product</condition>
  <condition>Tobacco Use</condition>
  <condition>Smoking, Tobacco</condition>
  <arm_group>
    <arm_group_label>Treatment with JUUL 5%, Virginia Tobacco</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JUUL 5%,Virginia Tobacco [5 days] in confinement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with JUUL 5%, Cool Mint, ENDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JUUL 5%, Cool Mint [5 days] in confinement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with JUUL 5%, Mango, ENDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JUUL 5%, Mango [5 days] in confinement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JUUL 5%, Creme Bruele, ENDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JUUL 5%, Creme Bruele [5 days] in confinement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combustible cigarette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exclusive use of combustible cigarette [5 days] in confinement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Smoking cessation (no smoking)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Smoking cessation (no smoking).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment with JUUL 5%, Virginia Tobacco</intervention_name>
    <description>JUUL 5%, ENDS for 5-days in confinement</description>
    <arm_group_label>Treatment with JUUL 5%, Virginia Tobacco</arm_group_label>
    <other_name>JUUL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment with JUUL 5%, Cool Mint, ENDS</intervention_name>
    <description>JUUL 5%, ENDS for 5-days in confinement</description>
    <arm_group_label>Treatment with JUUL 5%, Cool Mint, ENDS</arm_group_label>
    <other_name>JUUL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment with JUUL 5%, Mango, ENDS</intervention_name>
    <description>JUUL 5%, ENDS for 5-days in confinement</description>
    <arm_group_label>Treatment with JUUL 5%, Mango, ENDS</arm_group_label>
    <other_name>JUUL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUUL 5%, Creme Bruele, ENDS</intervention_name>
    <description>JUUL 5%, ENDS for 5-days in confinement</description>
    <arm_group_label>JUUL 5%, Creme Bruele, ENDS</arm_group_label>
    <other_name>JUUL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Combustible cigarette</intervention_name>
    <description>Exclusive use of combustible cigarette for 5 days in confinement.</description>
    <arm_group_label>Combustible cigarette</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Smoking Cessation</intervention_name>
    <description>No smoking for 5-days in confinement.</description>
    <arm_group_label>Smoking cessation (no smoking)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Healthy, adult, male or female smoker, 21 to 65 years of age.

          2. Has been a smoker for at least 12 months prior to Screening.

          3. Currently smokes an average of 10 cigarettes each day.

          4. Has a positive urine cotinine (â‰¥ 500 ng/mL).

          5. Has an exhaled carbon monoxide (CO) &gt; 12 ppm.

          6. A female subject of childbearing potential must have been using contraception and
             agree to continue using it through completion of the study:

          7. Provides voluntary consent to participate in this study documented on the signed
             informed consent form (ICF).

        Key Exclusion Criteria

          1. Has a history or presence of clinically significant conditions.

          2. Has a body mass index (BMI) &gt; 40 kg/m2 or &lt; 18 kg/m2 at Screen

          3. Has a history of drug or alcohol abuse

          4. Has an estimated creatinine clearance &lt; 80 mL/minute

          5. If female, the subject is pregnant, lactating, or intends to become pregnant during
             the time period from Screening through the end of study.

          6. Has used nicotine-containing products other than manufactured cigarettes within 14days
             of screening.

          7. Is planning to quit smoking during the study, planning to quit within 3 months
             following Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Mathew, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Concetta Carbonaro</last_name>
    <phone>415-855-5565</phone>
    <email>concetta@juul.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ziad Rouag</last_name>
    <phone>415-531-4647</phone>
    <email>ziad@juul.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Hambek</last_name>
      <phone>402-476-2811</phone>
      <email>steve.hambek@celerion.com</email>
    </contact>
    <contact_backup>
      <last_name>Jancie Slay</last_name>
      <phone>602 437 0097</phone>
      <email>janice.slay@celerion.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>HIPAA Privacy Rule. Information for Researchers. De-identifying Protected Health Information Under the Privacy Rule. U.S. Department of Health and Human Services. NIH (Feb 2007). Available at: http://privacyruleandresearch.nih.gov/pr_08.asp#8a. Last accessed 31-Jul-2017.</citation>
  </reference>
  <results_reference>
    <citation>D'Ruiz CD, Graff DW, Robinson E. Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes. BMC Public Health. 2016 Jul 11;16:543. doi: 10.1186/s12889-016-3236-1.</citation>
    <PMID>27401980</PMID>
  </results_reference>
  <results_reference>
    <citation>Jensen RP, Luo W, Pankow JF, Strongin RM, Peyton DH. Hidden formaldehyde in e-cigarette aerosols. N Engl J Med. 2015 Jan 22;372(4):392-4. doi: 10.1056/NEJMc1413069.</citation>
    <PMID>25607446</PMID>
  </results_reference>
  <results_reference>
    <citation>McNeill A et al. E-cigarettes: An Evidence Update. A report commissioned by Public Health England. Available at: https://www.gov.uk/government/uploads/system/uploads/ attachment_data/file/457102/Ecigarettes_an_evidence_update_A_report_commissioned_by_ Public_Health_England_FINAL.pdf (Aug 2015).</citation>
  </results_reference>
  <results_reference>
    <citation>Polosa R, Morjaria J, Caponnetto P, Caruso M, Strano S, Battaglia E, Russo C. Effect of smoking abstinence and reduction in asthmatic smokers switching to electronic cigarettes: evidence for harm reversal. Int J Environ Res Public Health. 2014 May 8;11(5):4965-77. doi: 10.3390/ijerph110504965.</citation>
    <PMID>24814944</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

